Jiangsu Yuyue Science & Technology Development

Jiangsu Yuyue Science & Technology Development

Jiangsu Yuyue Science & Technology Development operates as the corporate investment vehicle for Yuwell Medical, the Danyang-based medical-device manufacturer founded by Wu Guangming. The parent company, listed on the Shenzhen Stock Exchange (ticker 002223), produces respiratory therapy devices, blood-pressure monitors, and home-oxygen equipment, giving the investment arm a direct operational lens into China's healthcare supply chain. Yuwell Medical was established in 1998 and has since grown through both organic R&D and serial M&A. The firm pursues early-stage venture investments, growth-equity rounds, and control-oriented strategic acquisitions — deploying from a corporate balance sheet rather than a blind-pool fund structure. Deal activity has historically clustered in medical devices and diagnostics. In a landmark 2018 transaction, Wu partnered with Jack Ma-backed Yunfeng Capital to acquire Italian ultrasound and MRI specialist Esaote, valuing the diagnostic-imaging firm at roughly €300 million (per Reuters, 2018). The firm also held a significant stake in Beijing Wandong Medical, a domestic medical-imaging-equipment maker, before selling that position to Midea Group in 2021 (per Midea Group disclosure, 2021). Beyond healthcare, the group participates in adjacent industrial and real-asset investments, including the Yuwell Shanghai Global Center, a commercial property in Shanghai. Wu Guangming retains founder-level control over both the operating company and the investment function, with his son Wu Qun serving as Yuwell Medical's CEO. The family's holding structure is not publicly detailed in a single audited entity-level AUM figure, and the corporate treasury's investable book is not reported separately from the listed operating company's balance sheet. In a notable cross-shareholding move, New Huadu Industrial Group — the vehicle of Fujian billionaire Chen Fashu — joined as a fellow strategic investor in Yunnan Baiyao, one of China's most iconic traditional-medicine companies, which counts Yuwell among its minority investors (per Caixin, 2019). The structural differentiator is the dual-track mandate: Jiangsu Yuyue Science & Technology Development can act as a traditional VC when backing early-stage medical-tech startups in China, yet it also operates as a buyout platform for state-adjacent or foreign healthcare assets, as evidenced by the cross-border Esaote deal. The firm maintains a corporate foundation, the Yuwell Foundation, as a separate philanthropic vehicle, mirroring governance structures seen at larger Chinese family-controlled enterprises.